These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 16402717

  • 1. [Genotype 1 superresponder treat for only 24 weeks].
    MMW Fortschr Med; 2005 Dec 15; 147(51-52):69. PubMed ID: 16402717
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Treatment duration for genotypes 2 and 3: still confusing after all these years.
    Jensen DM.
    J Clin Gastroenterol; 2010 Sep 15; 44(8):527-8. PubMed ID: 20628314
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
    Lopukhova NL.
    Eksp Klin Gastroenterol; 2007 Sep 15; (4):146-52. PubMed ID: 18409502
    [No Abstract] [Full Text] [Related]

  • 6. [Peginterferon-alfa-2b or -alfa-2a and ribavirin combined treatment in hepatitis C infection].
    Szalay F.
    Orv Hetil; 2010 Feb 14; 151(7):271-3. PubMed ID: 20133247
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C.
    Aghemo A, Rumi MG, Colombo M.
    Expert Rev Anti Infect Ther; 2009 Oct 14; 7(8):925-35. PubMed ID: 19803700
    [Abstract] [Full Text] [Related]

  • 9. Hepatitis C treatment, HAART and side effects.
    TreatmentUpdate; 2001 Oct 14; 13(7):7-8. PubMed ID: 11794865
    [No Abstract] [Full Text] [Related]

  • 10. Peginterferon and ribavirin for chronic hepatitis C.
    Hoofnagle JH, Seeff LB.
    N Engl J Med; 2006 Dec 07; 355(23):2444-51. PubMed ID: 17151366
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.
    Yu ML, Dai CY, Huang JF, Chuang WL.
    Hepatology; 2008 Sep 07; 48(3):1019-20; author reply 1020-1. PubMed ID: 18756469
    [No Abstract] [Full Text] [Related]

  • 14. Response-guided therapy: optimizing treatment now and in the future.
    Marcellin P, Rizzetto M.
    Antivir Ther; 2008 Sep 07; 13 Suppl 1():1-2. PubMed ID: 18432156
    [No Abstract] [Full Text] [Related]

  • 15. Occurrence of hepatocellular carcinoma 13 years after successful antiviral treatment for HCV infection.
    Puoti C, Lanzetta G, Scotti E.
    J Gastrointestin Liver Dis; 2016 Sep 07; 25(3):408-9. PubMed ID: 27689211
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Optimal dosage of ribavirin.
    Mangia A, Andriulli A.
    Hepatology; 2010 Sep 07; 52(3):1174. PubMed ID: 20812365
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.